MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer

Kyoichi Kairaa Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka City, JapanCorrespondence[email protected]

Tomohiro Ikezawab Department of Nephrology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Moroyama-cho, Japan

Tsutomu Inoueb Department of Nephrology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Moroyama-cho, Japan

Hisao Imaia Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka City, Japan

Hirokazu Okadab Department of Nephrology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Moroyama-cho, Japan

Hiroshi Kagamua Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka City, Japan

"MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer." Journal of Chemotherapy, 36(1), pp. 82–83

Acknowledgments

We would like to thank Editage (www.editage.com) for English language editing.

Data availability statement

The data that support the findings of this study are available from the corresponding author, [K.K], upon reasonable request.

Disclosure statement

KK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Boehringer Ingelheim, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan, and AstraZeneca. HK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Bristol-Myers Company, Boehringer Ingelheim, MSD, Daiichi Sankyo Company, Chugai Pharmaceutical, Taiho Pharmaceutical, Merck Biopharma Company, Eli Lilly Japan, and AstraZeneca.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer

Information for

Open access

Opportunities

Help and information

MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer

Acknowledgments

Data availability statement

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature